In their own words, advocacy groups and patients acknowledge the important work being done by Lundbeck:

"ATryn offers a meaningful therapy to patients with hereditary antithrombin deficiency who are at increased risk of blood clots, especially during major surgical procedures or childbirth."

- Dr. Stephan Moll
Hematologist, University of North Carolina and Medical Director of the National Alliance for Thrombosis and Thrombophilia (www.stoptheclot.org)

"While the Huntington's disease community continues to passionately search for a cure for HD, the availability of Xenazine in the United States is an extraordinary advancement for those who are affected by chorea associated with Huntington’s disease. Lundbeck‘s commitment to make Xenazine available to patients through the extensive and generous assistance programs they have developed is truly commendable."

-Nancy Wexler
President, Hereditary Disease Foundation (HDF)

_________________________________________________________________________________________

"To be perfectly frank about drug companies that manufacture drugs for rare diseases, WE NEED THEM MORE THAN THEY NEED US."

-Desiree Lyon Howe
Executive Director, American Porphyria Foundation (APF)
 
_________________________________________________________________________________________

"Tuberous sclerosis complex (TSC) is a devastating genetic disease causing tumor growth in vital organs. Approximately 80-90% of individuals with TSC have epilepsy and up to one third of children experience Infantile Spasms, one of the most catastrophic types of seizures. The trusted partnership between the Tuberous Sclerosis Alliance and Lundbeck will help ensure that families coping with the serious consequences of TSC will have access to a vitally needed treatment for infantile spasms."

- Kari Luther Carlson
President and CEO, Tuberous Sclerosis Alliance